The possibility that dominant pathway on growth and survival of the NSCLC cells shifts from EGFR pathway partially to bypass signal pathways such as AXL by EGFR inhibitor treatment is considered, however, it is not clear. Here, EGFR is linked to non-small cell lung carcinoma.